Boston, MA – According to filings with the U.S. Securities and Exchange Commission, Jnana Therapeutics is raising $107,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Joanne Kotz played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Jnana Therapeutics
Jnana Therapeutics is a clinical-stage biotechnology company leveraging its next-generation chemoproteomics RAPID platform to discover medicines for highly validated, challenging-to-drug targets to treat diseases with high unmet need. Jnana is focused on developing first- and best-in-class therapies to treat a wide range of diseases, including rare diseases, immune-mediated diseases and cancer. Jnanas wholly owned lead program is a potential first-in-class oral approach, targeting an allosteric site on the phenylalanine transporter SLC6A19, for the treatment of phenylketonuria (PKU), a rare genetic metabolic disease. Located in Boston, Jnana brings together scientific leaders in small molecule drug discovery and development, a highly experienced management team and the backing of leading life science investors Bain Capital Life Sciences, RA Capital Management, Polaris Partners, Versant Ventures, Avalon Ventures, Pfizer Ventures and AbbVie Ventures. For more information, please visit www. jnanatx.com and follow us on Twitter and on LinkedIn.

To learn more about Jnana Therapeutics, visit http://www.jnanatx.com/

Contact:
Joanne Kotz, Chief Executive Officer
857-349-9200

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved